This article summarized the latest R&D progress of Prazepam, the Mechanism of Action for Prazepam, and the drug target R&D trends for Prazepam.

The 2023 ESMO Congress marked a pivotal moment with the disclosure of a clinical trial for Osimertinib mesylate in EGFR-mutated NSCLC patients, opening avenues for further increases in its clinical efficacy.

Last year belonged to the realm of Pfizer's COVID-19 small molecule treatments, while this year is dominated by GLP-1 injectable and oral therapies.

The overexpression of the anti-apoptotic factor Myeloid Cell Leukemia 1 (MCL-1), caused by the activation of CDK9, will lead to the transformation of malignant tumor cells. Therefore, inhibiting CDK9 will downregulate MCL-1, thereby suppressing tumor growth.

This article summarized the latest R&D progress of Raloxifene Hydrochloride, the Mechanism of Action for Raloxifene Hydrochloride, and the drug target R&D trends for Raloxifene Hydrochloride.

The recent ESMO Congress presented noteworthy clinical trial results of Givastomig, paving the way for a detailed exploration of its therapeutic potential in solid tumors.

A ketoreductase enzyme has undergone a gene mutation at a certain mutation site and has acquired a mutant enzyme with higher activity. How can one search for publicly available sequences of such enzyme mutants, as well as other popular mutation sites?

Small-molecule CDK2 selective inhibitors would be significant chemical probes for dissecting cellular processes or understanding the basics of diseases.

This article summarized the latest R&D progress of Reslizumab, the Mechanism of Action for Reslizumab, and the drug target R&D trends for Reslizumab.

On 23 Oct 2023, GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) was reported at the ESMO Congress.

This article will teach you three methods to find the corresponding sequence information by the name of an antibody.

Inhibitors of CD38 are a kind of treatment aimed at the white blood cells within bone marrow, which are responsible for inducing multiple myeloma.